Financial Performance - The estimated net profit for 2024 is projected to be 38 million CNY, a decrease of 55.97% compared to the previous year's profit of 86.31 million CNY[3] - The net profit after deducting non-recurring gains and losses is expected to be 35 million CNY, down 52.44% from 73.59 million CNY in the same period last year[3] Cost Factors - The decline in performance is attributed to increased costs from the company's equity incentive plan and amortization of intangible assets from the acquisition of Henan Xinxin Pharmaceutical[5] - Online promotion expenses have increased significantly to capture the market for Jieryin personal care products, contributing to the overall cost increase[5] Government Impact - Government subsidies have decreased, impacting the net profit by approximately 3 million CNY, a reduction of about 9.7 million CNY year-on-year[6]
恩威医药(301331) - 2024 Q4 - 年度业绩预告